Form 8-K - Current report
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s Telephone Number, Including Area Code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On August19, 2024, Coya Therapeutics, Inc. (the “Company”) announced a planned change in management. Effective November1, 2024, Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company. Dr.Swaminathan will succeed Dr.Howard Berman, who, on August16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October31, 2024. After his resignation, Dr.Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board. Upon his resignation, the Company anticipates that it will enter a consulting agreement with Dr.Berman, with an expected term of 12 months, pursuant to which Dr.Berman will provide consulting services to the Company.
On August19, 2024, upon recommendation of the Company’s Nominating and Corporate Governance Committee, Dr.Swaminathan was also appointed to the Company’s Board as a ClassIII director to serve until the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified.
Dr.Swaminathan, age 55, has served as the Company’s Chief Business Officer since April 2023. From September 2021 through March 2023, Dr.Swaminathan served as the Chief Business Officer of Actinium Pharmaceuticals, Inc. From December 2018 through September 2021, he served as the Chief Business Officer of Alteogen Inc. Dr.Swaminathan has 20+ years of experience in the pharmaceutical and biotechnology industries across commercial, business development and research and development roles. Dr.Swaminathan holds a bachelor of pharmacy from University of Madras, a Ph.D. in Pharmaceutical Sciences from University of Pittsburgh and is a graduate of the certificate program in Marketing Management from Wharton, University of Pennsylvania. The Company believes Dr.Swaminathan is qualified to serve on the Board due to his experience as the Company’s Chief Business Officer and his experience in the pharmaceutical and biotechnology industries.
Dr.Swaminathan is party to and currently serves the Company pursuant to the terms of an Executive Employment Agreement dated April3, 2023 (the “Employment Agreement”). Dr.Swaminathan’s current base salary is $425,000, and Dr.Swaminathan is eligible to receive an annual bonus for the fiscal year ending December31, 3024 in an amount equal to 40% of his base salary. Pursuant to the terms of the Employment Agreement, in the event Dr.Swaminathan is terminated without cause, he is eligible to receive continued payment of his base salary for 9 months. In connection with the transition of his role to Chief Executive Officer, the Compensation Committee of the Board plans to review and evaluate potential changes to Dr.Swaminathan’s compensation arrangements in light of what will be his new and increased responsibilities with the Company. Any changes to compensation will be subject to final determination and approval of the Compensation Committee upon completion of such review. Dr.Swaminathan is also party to an indemnification agreement on the Company’s standard form with each of its directors and executive officers, a copy of which was previously filed as Exhibit 10.2 to the Company’s Registration Statement on Form S-1 on November18, 2022.
-2-
The foregoing description of the Employment Agreement is not complete, and is subject to the full text of the Employment Agreement, a copy of which is included as Exhibit 10.1 to this Current Report on Form 8-K.
There are no arrangements or understandings between Dr.Swaminathan and any other person pursuant to which he was appointed as an officer or director and Dr.Swaminathan does not have a direct or indirect material interest in any “related party” transaction required to be separately disclosed pursuant to Item 404(a) of Regulation S-K. Dr.Swaminathan does not have any family relationships with any of the Company’s directors or executive officers.
| Item 7.01. | Regulation FD. |
On August19, 2024, the Company issued a press release announcing Dr.Swaminathan’s promotion to Chief Executive Officer effective November1, 2024. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | Description | |
| 10.1 | Executive Employment Agreement by and between the Company and Arun Swaminathan, dated April3, 2023. | |
| 99.1 | Press Release, dated August19, 2024. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
-3-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COYA THERAPEUTICS, INC. | ||||||
| Date: August19, 2024 | By: | /s/ Howard Berman | ||||
| Name: | Howard Berman | |||||
| Title: | Chief Executive Officer | |||||
-4-
Exhibit 10.1
EXECUTIVE EMPLOYMENT AGREEMENT
ThisExecutive Employment Agreement (Agreement), dated April 3, 2023 (Effective Date), is between Coya Therapeutics, Inc. (the Company) and Arun Swaminathan (Executive).
| 1. | Position, Responsibilities, and term |
| a. | Position. Executive is employed by the Company to render services to the Company in the position ofChief Business Officer. Executive shall perform such duties and responsibilities as are normally related to such position in accordance with the standards of the industry and any additional duties now or hereafter assigned to Executive by theCompanys Board of Directors (Board) (Services). Executive shall abide by the rules, regulations, and practices as adopted or modified from time to time in the Companys sole discretion. Executive willdevote Executives full- time efforts to the provision of Services under this Agreement. If the Executive is transferred to another position within the Company by the Board during the Term, Executive will continue to receive the compensationand benefits set forth in Section2. |
| b. | Other Activities. Except upon the prior written consent of the Company, Executive will not, during theterm of this Agreement: (i)be employed elsewhere; (ii)engage, directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that might interfere with Executives duties and responsibilitieshereunder or create a conflict of interest with the Company; or (iii)acquire any interest of any type in any other business which is in competition with the Company, provided, however, that the foregoing shall not be deemed to prohibit theExecutive from acquiring solely as an investment up to one percent (1%) of the outstanding equity interests of any publicly-held company. |
| c. | No Conflict. Executive represents and warrants that Executives execution of this Agreement andperformance of Services under this Agreement will not violate any obligations Executive may have to any other employer, person or entity, including any obligations to keep in confidence proprietary information, knowledge, or data acquired byExecutive in confidence or in trust prior to becoming an employee of the Company. |
| d. | Term of Employment. The initial term of this Agreement shall be for a period of (i) two (2)yearsafter the Effective Date of this Agreement (Initial Term); or (ii)the date upon which Executives employment is terminated in accordance with Section3. This Agreement shall be automatically renewed for additionalone (1)year terms (each an Extension Term) upon the expiration of the Initial Term and each Extension Term, unless either party gives the other party a written notice of termination not less than thirty (30)days priorto the date of expiration of the Initial Term or any Extension Term (together, the Initial Term and all Extension Terms are referred to herein as the Term). Where the Agreement is terminated upon notice and the expiration of theInitial Term or an Extension Term, the Company shall pay to Executive all compensation to which Executive is entitled up through the effective date of termination according to its normal payroll practices, and the Company shall not have any furtherobligations under this Agreement. |
| 2. | Compensation and Benefits |
| a. | Base Salary. In consideration of the Services to be rendered under this Agreement, the Company shall payExecutive a gross salary at the rate of $375,000 per year (Base Salary), less applicable withholdings. The Base Salary shall be paid in accordance with the Companys normal payroll practices. Executives Base Salary willbe reviewed from time to time in accordance with the established procedures of the Company for adjusting salaries for similarly situated employees and may be adjusted in the sole discretion of the Company. |
| b. | Annual Bonus. In further consideration of the Services to be rendered under this Agreement, Executiveshall be eligible to receive an annual bonus of up to 35% of Base Salary, less applicable withholdings, based on achievement of goals and objectives established by the Company (Annual Bonus). Any Annual Bonus earned by Executivewill be paid within two-and-one-half months of the end of the year in which it was earned. Executive must remain employed withthe Company through the end of the calendar year at issue in order to be eligible to receive the Annual Bonus. |
| c. | Employment Benefits Plans. In further consideration of the Services to be rendered under this Agreement,Executive will be entitled to participate in pension, profit sharing and other retirement plans, incentive compensation plans, group health, hospitalization and disability or other insurance plans, and other employee welfare benefit plans generallymade available to other similarly-situated employees of the Company, in accordance with the benefit plans established by the Company, and as may be amended from time to time in the Companys sole discretion. |
| d. | Vacation. Executive shall be eligible to receive paid vacation consistent with the policies andprocedures adopted by the Company, if any, in its sole discretion. |
| e. | Equity Plan. Executive shall be granted options 115,000 of Coyas common stock at a strike priceequal to the fair market value on the date of grant. One third of these options will vest at the one-year anniversary of the grant and the remainder shall vest ratably over the subsequent 24 months. |
| f. | Expenses. The Company will pay or reimburse Executive for all normal and reasonable travel andentertainment expenses incurred by Executive in connection with Executives responsibilities to the Company upon submission of proper vouchers and documentation in accordance with the Companys expense reimbursem*nt policy. |
| 3. | At-Will Employment |
The employment of Executive shall be at-will at all times. The Company or Executive mayterminate Executives employment with the Company at any time, without any advance notice, for any reason or no reason at all, notwithstanding anything to the contrary contained in or arising from any statements, policies or practices of theCompany relating to the employment, discipline or termination of its employees. Following the termination of Executives employment, the Company shall pay to Executive all compensation to which Executive is entitled up through the date oftermination. Thereafter, all obligations of the Company under this Agreement shall cease other than those set forth in Section4.
2
| 4. | Company Termination Obligations |
| a. | Termination by Company for Cause. Where the Company terminates Executives employment for Cause,all obligations of the Company under this Agreement shall cease, other than those set forth in Section3. For purposes of this Agreement, Cause shall mean: (i)Executive engages in misconduct, including but not limitedto misappropriation of trade secrets, fraud, or embezzlement; (ii)Executive commits a crime involving dishonesty, breach of trust, or physical harm to any person; (iii)Executive breaches this Agreement; (iv)Executive refuses toimplement or follow a lawful policy or directive of the Company; (v)Executive engages in misfeasance or malfeasance demonstrated by Executives failure to perform Executives job duties diligently and/or professionally; or(vi)Executive violates a Company policy or procedure which causes harm to the Company, including violation of the Companys policy concerning sexual harassment, discrimination or retaliation. |
| b. | Termination by Company without Cause. For that period commencing as of the Effective Date until the oneyear anniversary of the Effective date, should the Company terminate Executives employment without Cause, and Executives employment is not terminated due to death or Disability (as defined below), Executive will be eligible to receivecontinued payment of Base Salary for three (3) months according to the Companys normal payroll practices, less applicable withholdings and any remuneration paid to Executive during each applicable Company payroll period because of Executivesemployment or self- employment during such period. Subsequent to the one year anniversary of the Effective Date, should the Company terminate Executives employment without Cause, and Executives employment is not terminated due to deathor Disability (as defined below), Executive will be eligible to receive continued payment of Base Salary for nine (9)months according to the Companys normal payroll practices, less applicable withholdings and any remuneration paid toExecutive during each applicable Company payroll period because of Executives employment or self- employment during such period. |
| c. | Termination Due to Disability. Executives employment shall terminate automatically if Executivebecomes Disabled. Executive shall be deemed Disabled if Executive is unable for medical reasons to perform Executives essential job duties for either ninety (90)consecutive calendar days or one hundred twenty (120)business days ina twelve (12)month period and, within thirty (30)days after a notice of termination is given to Executive, Executive has not returned to work. If Executives employment is terminated by the Company due to ExecutivesDisability, all obligations of the Company under this Agreement shall cease, other than those set forth in Section3. |
| d. | Termination Due to Death. Executives employment shall terminate automatically uponExecutives death. If Executives employment is terminated due to Executives death, all obligations of the Company under this Agreement shall cease, other than those set forth in Section3. |
3
| e. | Executives Resignation. Executive may resign Executives employment at any time during theTerm of this Agreement pursuant to Section3, and thereafter, all obligations of the Company under this Agreement shall cease, other than those set forth in Section3. |
| f. | Timing of Payments. In the event that Executive becomes entitled to receive continued payment of BaseSalary pursuant to Section4(b), Executive shall not be entitled to receive any such payments until the Companys first payroll date that is coincident with or next following the date that is fifty five (55)calendar days followingthe date of Executives termination of employment (or, if applicable, the date of Executives Separation from Service) and any payments that otherwise would have been paid to Executive during such period shall be paid to Executive with thefirst installment paid to Executive following the end of such period. Any pro-rated Annual Bonus that becomes payable to Executive pursuant to Section4(b) shall be paid to Executive in a lump sum paymenton the date that Executive receives the first installment payment of continued Base Salary as provided in the preceding sentence. |
| g. | Section409A; Delayed Payments. To the extent applicable, the provisions in thisSection4 are intended to comply with Section409A of the Internal Revenue Code of 1986, as amended, and guidance promulgated thereunder (409A) and this Agreement shall be administered and construed in a mannerconsistent with this intent. In the event that any compensation that becomes payable to Executive pursuant to this Section4 qualifies as a deferral of compensation within the meaning of and subject to 409A, then, notwithstanding anything tothe contrary in this Agreement (i)such compensation shall be paid to Executive only in the event of Executives separation from service with the Company within the meaning of 409A (Separation from Service)and (ii)payment of that compensation shall be delayed if Executive is a specified employee, as defined in 409A(a)(2)(B)(i), and such delayed payment is required by 409A. Such delay shall last six (6)months from thedate of Executives Separation from Service. On the Companys first payroll date that occurs after the end of such six-month period, the Company shall make acatch-up payment to Executive equal to the total amount of such payments that would have been made during the six-month period but for this Section4(g). To theextent applicable, each and every payment to be made pursuant to Section4(b) shall be treated as a separate payment and not as one of a series of payments treated as a single payment for purposes of Treasury Regulation Section1.409A-2(b)(2)(iii). |
| 5. | Executive Termination Obligations |
| a. | Return of Property. Executive agrees that all property (including without limitation all equipment,tangible proprietary information, documents, records, notes, contracts and computer-generated materials) furnished to or created or prepared by Executive incident to Executives employment belongs to the Company and shall be promptly returnedto the Company upon termination of Executives employment. |
4
| b. | Resignation and Cooperation. Upon termination of Executives employment, Executive shall be deemedto have resigned from all offices and directorships then held with the Company. Following any termination of employment, Executive shall cooperate with the Company in the winding up of pending work on behalf of the Company and the orderly transferof work to other employees. Executive shall also cooperate with the Company in the defense of any action brought by any third party against the Company that relates to Executives employment by the Company. |
This Agreement may not be amended or waived except by a writing signed by Executive and by the Companys Board. Failure to exercise any right under thisAgreement shall not constitute a waiver of such right. Any waiver of any breach of this Agreement shall not operate as a waiver of any subsequent breaches. All rights or remedies specified for a party herein shall be cumulative and in addition toall other rights and remedies of the party hereunder or under applicable law.
| 6. | Assignment; Binding Effect |
| a. | Assignment. The performance of Executive is personal hereunder, and Executive agrees that Executiveshall have no right to assign and shall not assign or purport to assign any rights or obligations under this Agreement. This Agreement may be assigned or transferred by the Company; and nothing in this Agreement shall prevent the consolidation,merger or sale of the Company or a sale of any or all or substantially all of its assets. |
| b. | Binding Effect. Subject to the foregoing restriction on assignment by Executive, this Agreement shallinure to the benefit of and be binding upon each of the parties; the affiliates, officers, directors, agents, successors and assigns of the Company; and the heirs, devisees, spouses, legal representatives and successors of Executive. |
| 7. | Notices |
All notices or other communications required or permitted hereunder shall be made in writing and shall be deemed to have been duly given if delivered:(a)by hand; (b)by a nationally recognized overnight courier service; or (c)by United States first class registered or certified mail, return receipt requested, to the principal address of the other party.
| 8. | Severability |
If any provision of this Agreement shall be held by a court or arbitrator to be invalid, unenforceable, or void, such provision shall be enforced to thefullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed themaximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall reduce the time period or scope to the maximum time period or scope permitted by law.
5
| 9. | Taxes |
All amounts paid under this Agreement shall be paid less all applicable state and federal tax withholdings and any other withholdings required by anyapplicable jurisdiction.
| 10. | Governing Law |
This Agreement shall be governed by and construed in accordance with the laws of the State of Texas.
| 11. | Interpretation |
This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Sections and section headings containedin this Agreement are for reference purposes only, and shall not affect in any manner the meaning or interpretation of this Agreement. Whenever the context requires, references to the singular shall include the plural and the plural the singular.
| 12. | Obligations Survive Termination of Employment |
Executive agrees that any and all of Executives obligations under this Agreement, shall survive the termination of employment and the termination of thisAgreement.
| 13. | Counterparts |
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original of this Agreement, but all of which together shallconstitute one and the same instrument.
| 14. | Authority |
Each party represents and warrants that such party has the right, power and authority to enter into and execute this Agreement and to perform and discharge allof the obligations hereunder; and that this Agreement constitutes the valid and legally binding agreement and obligation of such party and is enforceable in accordance with its terms.
| 15. | Entire Agreement |
This Agreement is intended to be the final, complete, and exclusive statement of the terms of Executives employment by the Company and may not becontradicted by evidence of any prior or contemporaneous statements or agreements, except for agreements specifically referenced herein (including the Award Agreement, Proprietary Information Agreement, and Mutual Arbitration Agreement. To theextent that the practices, policies or procedures of the Company, now or in the future, apply to Executive and are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change inExecutives duties, position, or compensation will not affect the validity or scope of this Agreement.
6
| 16. | Executive Acknowledgement |
EXECUTIVE ACKNOWLEDGES EXECUTIVE HAS HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL CONCERNING THIS AGREEMENT, THAT EXECUTIVE HAS READ AND UNDERSTANDS THEAGREEMENT, THAT EXECUTIVE IS FULLY AWARE OF ITS LEGAL EFFECT, AND THAT EXECUTIVE HAS ENTERED INTO IT FREELY BASED ON EXECUTIVES OWN JUDGMENT AND NOT ON ANY REPRESENTATIONS OR PROMISES OTHER THAN THOSE CONTAINED IN THIS AGREEMENT.
IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first written above.
| COYA THERAPEUTICS, INC. | EXECUTIVE | |||||||
| By: | By: | |||||||
| Howard Berman, CEO | Arun Swaminathan | |||||||
| Dated: | Dated: | |||||||
7
Exhibit 99.1
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
Dr. Howard Berman, the founder of Coya, will transition to Executive Chairof the Board effective November 1st, 2024
Dr.Arun Swaminathan is appointed to the Board of Directors effective immediately
HOUSTON, TX, August 19, 2024 Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stagebiotechnology company developing biologics intended to enhance regulatory T cell (Treg) function today announced that Arun Swaminathan Ph.D. has been promoted to the role of Chief Executive Officer effective November1, 2024. He will succeedDr.Howard Berman who will continue to serve in the capacity of Executive Chair.
As we look forward to and prepare for the release ofAlzheimers data at the upcoming CTAD24 conference on October29, 2024 in Madrid and continue to progress COYA 302 in ALS, the company will benefit from leveraging Dr.Swaminathans strategic, business development,operational, and deal making experience to guide Coya through its next phase in the companys growth. Over the last 5 years across multiple companies, Dr.Swaminathan was instrumental in executing several company significantcommercial transactions in excess of $6billion, including Coyas recent Dr.Reddys Laboratory licensing transaction of up to $700million.
Coya also believes it will benefit from Dr.Swaminathans leadership in advancing COYA 302 in related programs such as Frontotemporal Dementia(FTD), Parkinsons Disease (PD), and other immune mediated diseases.
Howard Berman, Ph.D., commented,Coyahas grown quicklyto a clinical stage company and is poised, in partnership with Dr.Reddys Laboratories, to potentially bring these therapies to patients who desperately need them.We believe Arun has an incredible skillset to executeon each of these milestones. Hehas been a foundational member ofthisteam,instrumental in consummating our up to$700million licensing transaction withDr.Reddys Laboratories. At this stage of our evolution, I can think of no one betterskilledand dedicatedto take us to the next level, to progress our assets forward intheclinic and execute new business deals, all of which we believe will create value for our shareholders.
Prior to joining Coya as our Chief BusinessOfficer, a role he has served in since April 2023, Dr.Swaminathan executed significant commercial transactions at Alteogen Inc. and Actinium Pharmaceuticals. He also was the founder and CEO of Lynkogen, Inc., a company developing GLP-1 fusionproteins. He began his career in clinical pharmacology and development and commercial roles of increasing responsibility at Bristol Myers Squibb and Covance and obtained his Ph.D. in pharmaceutical sciences from the University of Pittsburgh.
Dr. Swaminathan added, Im excited and grateful for the confidence Howard and our board of directors have placed in me. I look forward toexpanding our existing partnerships and continuing to leverage my long-standing relationships and knowledge of the industry on behalf of the company and its shareholders, building atop the strong foundation weve together created over the lastyear. It is my mandate to bring our assets to patients as quickly as possible.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on thebiology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmunediseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.
Coyas investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatoryfunctions of Tregs. Coyas therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
COYA 302 the Companys lead biologic investigational product or Pipeline in a Product is a proprietary combination of COYA 301 (Coyas proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinsons Disease, andAlzheimers Disease.Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion ofpro-inflammatory mediators.This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained anddurable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.
For more information about Coya, please visitwww.coyatherapeutics.com
Forward-Looking Statements
This press release containsforward-looking statements that are based on our managements beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical factcontained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing andplanned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of ourproduct candidates, competitive position, industry environment and potential market opportunities. The words believe, may, will, estimate, continue, anticipate,intend, expect, and similar expressions are intended to identify forward-looking statements.
Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and otherfactors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and plannedclinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinicaltrials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development andcommercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of themarkets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our productcandidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability toattract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue,capital requirements and needs for additional financing.
We have based these forward-looking statements largely on our current expectations andprojections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a verycompetitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, orcombination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circ*mstances discussedherein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements arereasonable, we cannot guarantee that the future results, levels of activity, performance or events and circ*mstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update anyforward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
David Snyder, CFO
david@coyatherapeutics.com
CORE IR
Bret Shapiro
brets@coreir.com
561-479-8566
Media Contacts
For CoyaTherapeutics:
Kati Waldenburg
media@coyatherapeutics.com
212-655-0924
Document and Entity Information | Aug. 16, 2024 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | false |
| Entity Central Index Key | 0001835022 |
| Document Type | 8-K |
| Document Period End Date | Aug. 16, 2024 |
| Entity Registrant Name | Coya Therapeutics, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-41583 |
| Entity Tax Identification Number | 85-4017781 |
| Entity Address, Address Line One | 5850 San Felipe St. |
| Entity Address, Address Line Two | Suite 500 |
| Entity Address, City or Town | Houston |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 77057 |
| City Area Code | 800 |
| Local Phone Number | 587-8170 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.0001 per share |
| Trading Symbol | COYA |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
Coya Therapeutics (NASDAQ:COYA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Coya Therapeutics (NASDAQ:COYA)
Historical Stock Chart
From Aug 2023 to Aug 2024
 | {{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}} |
Loading Messages....
Coya Therapeutics Inc News
Loading Messages....
`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `
`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `
FEATURED
•{{ article.source }} • {{ article.date}} {{article.time}}
`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Mawson Finland Provides Update on Exploration Activities at Rajapalot","link":"https:\/\/ih.advfn.com\/common\/newswire\/ct\/MjIxNg==","timestamp":1724241992,"date":"Wed Aug 21, 2024 ","time":"8:06 AM (3 hours ago)","isPromoted":true},{"headline":"Form 3 - Initial statement of beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94416138\/form-3-initial-statement-of-beneficial-ownership","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1724183786,"date":"Tue Aug 20, 2024 ","time":"3:56 PM (19 hours ago)","full_date":"August 20, 2024 3:56 PM","post_time":"19 hours ago","article_id":94416138,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94406335\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1724073000,"date":"Mon Aug 19, 2024 ","time":"9:10 AM (2 days ago)","full_date":"August 19, 2024 9:10 AM","post_time":"August 19 2024","article_id":94406335,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024","short_text":"\nDr. Howard Berman, the founder of Coya, will transition to Executive Chair of the Board effective November 1st, 2024 Dr. Arun Swaminathan is appointed to the Board of Directors effective...","one_line_short_text":"\nDr. Howard Berman, the founder of Coya, will transition to Executive Chair of the Board effective November 1st, 2024 Dr. Arun Swaminathan is...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94406142\/coya-therapeutics-promotes-arun-swaminathan-ph-d","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1724072400,"date":"Mon Aug 19, 2024 ","time":"9:00 AM (2 days ago)","full_date":"August 19, 2024 9:00 AM","post_time":"August 19 2024","article_id":94406142,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94361731\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1723464827,"date":"Mon Aug 12, 2024 ","time":"8:13 AM (1 week ago)","full_date":"August 12, 2024 8:13 AM","post_time":"August 12 2024","article_id":94361731,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94361675\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1723464266,"date":"Mon Aug 12, 2024 ","time":"8:04 AM (1 week ago)","full_date":"August 12, 2024 8:04 AM","post_time":"August 12 2024","article_id":94361675,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results","short_text":"\nCoya Therapeutics, Inc. (Nasdaq: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a...","one_line_short_text":"\nCoya Therapeutics, Inc. (Nasdaq: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94361580\/coya-therapeutics-provides-a-corporate-update-and","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1723464000,"date":"Mon Aug 12, 2024 ","time":"8:00 AM (1 week ago)","full_date":"August 12, 2024 8:00 AM","post_time":"August 12 2024","article_id":94361580,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer\u2019s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer\u2019s Disease Conference (CTAD24) in Madrid","short_text":"\nCoya had previously announced that initial topline data from this Investigator Initiated Trial (IIT) may be presented in Summer 2024. The Houston Methodist Research Institute investigators...","one_line_short_text":"\nCoya had previously announced that initial topline data from this Investigator Initiated Trial (IIT) may be presented in Summer 2024. The Houston...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94305902\/coya-therapeutics-announces-that-results-from-a-do","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1722600900,"date":"Fri Aug 02, 2024 ","time":"8:15 AM (3 weeks ago)","full_date":"August 2, 2024 8:15 AM","post_time":"August 02 2024","article_id":94305902,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists","short_text":"\nCombination of COYA 301 + GLP-1 receptor agonists (GLP-1 RA) may present a promising multi-pathway targeted approach for additive and\/or synergistic anti-inflammatory functions for the potential...","one_line_short_text":"\nCombination of COYA 301 + GLP-1 receptor agonists (GLP-1 RA) may present a promising multi-pathway targeted approach for additive and\/or...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94283929\/coya-therapeutics-expands-pipeline-and-intellectua","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1722428100,"date":"Wed Jul 31, 2024 ","time":"8:15 AM (3 weeks ago)","full_date":"July 31, 2024 8:15 AM","post_time":"July 31 2024","article_id":94283929,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94191769\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1721038201,"date":"Mon Jul 15, 2024 ","time":"6:10 AM (1 month ago)","full_date":"July 15, 2024 6:10 AM","post_time":"July 15 2024","article_id":94191769,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic","short_text":"\nJoint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a first-in-human clinical study, continue work on...","one_line_short_text":"\nJoint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94077347\/coya-therapeutics-expands-sponsored-research-colla","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1718885700,"date":"Thu Jun 20, 2024 ","time":"8:15 AM (2 months ago)","full_date":"June 20, 2024 8:15 AM","post_time":"June 20 2024","article_id":94077347,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Form S-3 - Registration statement under Securities Act of 1933","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94047194\/form-s-3-registration-statement-under-securities","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1718398867,"date":"Fri Jun 14, 2024 ","time":"5:01 PM (2 months ago)","full_date":"June 14, 2024 5:01 PM","post_time":"June 14 2024","article_id":94047194,"source_id":"edgar2","media_url":null,"press_release":true}],"All News": [{"headline":"Mawson Finland Provides Update on Exploration Activities at Rajapalot","link":"https:\/\/ih.advfn.com\/common\/newswire\/ct\/MjIxNg==","timestamp":1724241992,"date":"Wed Aug 21, 2024 ","time":"8:06 AM (3 hours ago)","isPromoted":true},{"headline":"Form 3 - Initial statement of beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94416138\/form-3-initial-statement-of-beneficial-ownership","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1724183786,"date":"Tue Aug 20, 2024 ","time":"3:56 PM (19 hours ago)","full_date":"August 20, 2024 3:56 PM","post_time":"19 hours ago","article_id":94416138,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94406335\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1724073000,"date":"Mon Aug 19, 2024 ","time":"9:10 AM (2 days ago)","full_date":"August 19, 2024 9:10 AM","post_time":"August 19 2024","article_id":94406335,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024","short_text":"\nDr. Howard Berman, the founder of Coya, will transition to Executive Chair of the Board effective November 1st, 2024 Dr. Arun Swaminathan is appointed to the Board of Directors effective...","one_line_short_text":"\nDr. Howard Berman, the founder of Coya, will transition to Executive Chair of the Board effective November 1st, 2024 Dr. Arun Swaminathan is...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94406142\/coya-therapeutics-promotes-arun-swaminathan-ph-d","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1724072400,"date":"Mon Aug 19, 2024 ","time":"9:00 AM (2 days ago)","full_date":"August 19, 2024 9:00 AM","post_time":"August 19 2024","article_id":94406142,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94361731\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1723464827,"date":"Mon Aug 12, 2024 ","time":"8:13 AM (1 week ago)","full_date":"August 12, 2024 8:13 AM","post_time":"August 12 2024","article_id":94361731,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94361675\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1723464266,"date":"Mon Aug 12, 2024 ","time":"8:04 AM (1 week ago)","full_date":"August 12, 2024 8:04 AM","post_time":"August 12 2024","article_id":94361675,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results","short_text":"\nCoya Therapeutics, Inc. (Nasdaq: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a...","one_line_short_text":"\nCoya Therapeutics, Inc. (Nasdaq: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94361580\/coya-therapeutics-provides-a-corporate-update-and","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1723464000,"date":"Mon Aug 12, 2024 ","time":"8:00 AM (1 week ago)","full_date":"August 12, 2024 8:00 AM","post_time":"August 12 2024","article_id":94361580,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer\u2019s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer\u2019s Disease Conference (CTAD24) in Madrid","short_text":"\nCoya had previously announced that initial topline data from this Investigator Initiated Trial (IIT) may be presented in Summer 2024. The Houston Methodist Research Institute investigators...","one_line_short_text":"\nCoya had previously announced that initial topline data from this Investigator Initiated Trial (IIT) may be presented in Summer 2024. The Houston...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94305902\/coya-therapeutics-announces-that-results-from-a-do","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1722600900,"date":"Fri Aug 02, 2024 ","time":"8:15 AM (3 weeks ago)","full_date":"August 2, 2024 8:15 AM","post_time":"August 02 2024","article_id":94305902,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists","short_text":"\nCombination of COYA 301 + GLP-1 receptor agonists (GLP-1 RA) may present a promising multi-pathway targeted approach for additive and\/or synergistic anti-inflammatory functions for the potential...","one_line_short_text":"\nCombination of COYA 301 + GLP-1 receptor agonists (GLP-1 RA) may present a promising multi-pathway targeted approach for additive and\/or...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94283929\/coya-therapeutics-expands-pipeline-and-intellectua","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1722428100,"date":"Wed Jul 31, 2024 ","time":"8:15 AM (3 weeks ago)","full_date":"July 31, 2024 8:15 AM","post_time":"July 31 2024","article_id":94283929,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94191769\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1721038201,"date":"Mon Jul 15, 2024 ","time":"6:10 AM (1 month ago)","full_date":"July 15, 2024 6:10 AM","post_time":"July 15 2024","article_id":94191769,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic","short_text":"\nJoint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a first-in-human clinical study, continue work on...","one_line_short_text":"\nJoint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94077347\/coya-therapeutics-expands-sponsored-research-colla","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1718885700,"date":"Thu Jun 20, 2024 ","time":"8:15 AM (2 months ago)","full_date":"June 20, 2024 8:15 AM","post_time":"June 20 2024","article_id":94077347,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Form S-3 - Registration statement under Securities Act of 1933","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/coya-therapeutics-COYA\/stock-news\/94047194\/form-s-3-registration-statement-under-securities","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1718398867,"date":"Fri Jun 14, 2024 ","time":"5:01 PM (2 months ago)","full_date":"June 14, 2024 5:01 PM","post_time":"June 14 2024","article_id":94047194,"source_id":"edgar2","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});
More Coya Therapeutics Inc News Articles
